ANDA 77368, held by Apotex Inc. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77368 (Ondansetron Hydrochloride), held by Apotex Inc, was first approved by FDA on Dec 26, 2006, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Mar 15, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 16, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 16, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 31, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 31, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 31, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 19, 2007 | Supplement 2Manufacturing | Approved | None posted |
| Jun 19, 2007 | Supplement 1Manufacturing | Approved | None posted |
| Dec 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters